Post-earnings recap
Reported
Mon, May 12, 2025
EPS actual
$-0.15
EPS est.
$-0.12
EPS surprise
-28.21%
1-day move
+14.01%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing on EPS expectations, ImmunityBio's stock rose by 14.01% following the earnings report. This increase may reflect investor optimism about the company's long-term potential, as management highlighted their commitment to future growth. The lack of revenue data and guidance may leave some investors cautious, but the stock's strong reaction suggests confidence in the company's direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.15 | N/A | -28.21% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed caution regarding current performance but reaffirmed their focus on future growth opportunities.
Management acknowledged the challenges faced this quarter.
They emphasized a commitment to long-term goals despite short-term setbacks.